IgA nephropathy: Optical leadership or structural advantage?

Healthcare

Foveal Research

Vertex's IgA nephropathy is being valued on perceived differentiation rather than durable commercial advantage. Foveal's report dissects how alignment, baseline architecture and segment economics reshape probability of success and peak sales assumptions across the class. They identify where consensus expectations appear stretched (VRTX, Vera) and where valuation leverage remains underappreciated (Otsuka, Novartis) ahead of key 2026 catalysts.

- 06 March, 2026

The pain trade: The new frontier of non-opioid treatments

Sustainable Market Strategies

America’s opioid crisis is a major societal issue largely ignored by the financial community, with devastating effects on the US economy and labour force participation. Although a large share of the blame must go to pharma companies that designed, manufactured and promoted the products, other parts of the healthcare sector also share responsibility. Current equity investors should note what role publicly-listed healthcare companies played and how they responded to accusations (see chart). Looking ahead, the implementation of the NOPAIN Act could mark a significant inflection point for investors seeking to address the opioid crisis through strategic capital allocation. Companies such as Pacira BioSciences, Indivior and Vertex Pharmaceuticals are leading efforts to provide alternatives to opioid dependence. By boosting non-opioid alternatives, the Act opens new investment avenues for impact-minded investors.

- 09 August, 2024